The Company intends to continue THB335 development activities through the first half of 2025 to prepare for the initiation of a 12-week, placebo-controlled Phase 2 study in CSU by mid-year 2025. Key near-term activities include completion of ongoing subchronic toxicology studies and submission of regulatory filings to position THB335 for Phase 2 initiation.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THRD:
- THRD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Third Harmonic Bio Advances THB335 for Inflammatory Diseases
- Biotech Alert: Searches spiking for these stocks today
- Third Harmonic Bio, Inc.: Hold Rating Amid Strategic Uncertainty and Safety Concerns
- Third Harmonic Bio downgraded to Equal Weight from Overweight at Morgan Stanley